Clinical Trial: Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Brief Summary: The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Detailed Summary:
Sponsor: Ziopharm

Current Primary Outcome: Response Rate [ Time Frame: 6 months ]

Original Primary Outcome:

Current Secondary Outcome: toxicities [ Time Frame: 6 months ]

Original Secondary Outcome:

Information By: Ziopharm

Dates:
Date Received: January 10, 2007
Date Started: December 2006
Date Completion:
Last Updated: July 18, 2012
Last Verified: July 2012